88 related articles for article (PubMed ID: 18594316)
1. Association of phosphorylated epidermal growth factor receptor with survival in patients with locally advanced non-small cell lung cancer treated with radiotherapy.
Tsakiridis T; Cutz JC; Singh G; Hirte H; Okawara G; Corbett T; Sur R; Cai W; Whelan T; Wright JR
J Thorac Oncol; 2008 Jul; 3(7):716-22. PubMed ID: 18594316
[TBL] [Abstract][Full Text] [Related]
2. Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
Cappuzzo F; Ligorio C; Jänne PA; Toschi L; Rossi E; Trisolini R; Paioli D; Holmes AJ; Magrini E; Finocchiaro G; Bartolini S; Cancellieri A; Ciardiello F; Patelli M; Crino L; Varella-Garcia M
J Clin Oncol; 2007 Jun; 25(16):2248-55. PubMed ID: 17538169
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
Han SW; Hwang PG; Chung DH; Kim DW; Im SA; Kim YT; Kim TY; Heo DS; Bang YJ; Kim NK
Int J Cancer; 2005 Jan; 113(1):109-15. PubMed ID: 15386420
[TBL] [Abstract][Full Text] [Related]
4. Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Kashihara M; Azuma K; Kawahara A; Basaki Y; Hattori S; Yanagawa T; Terazaki Y; Takamori S; Shirouzu K; Aizawa H; Nakano K; Kage M; Kuwano M; Ono M
J Thorac Oncol; 2009 Sep; 4(9):1066-74. PubMed ID: 19648825
[TBL] [Abstract][Full Text] [Related]
5. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
[TBL] [Abstract][Full Text] [Related]
7. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.
Pirker R; Pereira JR; von Pawel J; Krzakowski M; Ramlau R; Park K; de Marinis F; Eberhardt WE; Paz-Ares L; Störkel S; Schumacher KM; von Heydebreck A; Celik I; O'Byrne KJ
Lancet Oncol; 2012 Jan; 13(1):33-42. PubMed ID: 22056021
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study.
Mazières J; Brugger W; Cappuzzo F; Middel P; Frosch A; Bara I; Klingelschmitt G; Klughammer B
Lung Cancer; 2013 Nov; 82(2):231-7. PubMed ID: 23972450
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis.
Tang JM; He QY; Guo RX; Chang XJ
Lung Cancer; 2006 Feb; 51(2):181-91. PubMed ID: 16324768
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F; Gregorc V; Rossi E; Cancellieri A; Magrini E; Paties CT; Ceresoli G; Lombardo L; Bartolini S; Calandri C; de Rosa M; Villa E; Crino L
J Clin Oncol; 2003 Jul; 21(14):2658-63. PubMed ID: 12860941
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Han SW; Kim TY; Hwang PG; Jeong S; Kim J; Choi IS; Oh DY; Kim JH; Kim DW; Chung DH; Im SA; Kim YT; Lee JS; Heo DS; Bang YJ; Kim NK
J Clin Oncol; 2005 Apr; 23(11):2493-501. PubMed ID: 15710947
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Chung FT; Lee KY; Wang CW; Heh CC; Chan YF; Chen HW; Kuo CH; Feng PH; Lin TY; Wang CH; Chou CL; Chen HC; Lin SM; Kuo HP
Int J Cancer; 2012 Aug; 131(3):E227-35. PubMed ID: 22174092
[TBL] [Abstract][Full Text] [Related]
13. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome.
Onn A; Choe DH; Herbst RS; Correa AM; Munden RF; Truong MT; Vaporciyan AA; Isobe T; Gilcrease MZ; Marom EM
Radiology; 2005 Oct; 237(1):342-7. PubMed ID: 16183941
[TBL] [Abstract][Full Text] [Related]
14. Activation state EGFR and STAT-3 as prognostic markers in resected non-small cell lung cancer.
Cortas T; Eisenberg R; Fu P; Kern J; Patrick L; Dowlati A
Lung Cancer; 2007 Mar; 55(3):349-55. PubMed ID: 17161498
[TBL] [Abstract][Full Text] [Related]
15. Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC).
Mukohara T; Kudoh S; Yamauchi S; Kimura T; Yoshimura N; Kanazawa H; Hirata K; Wanibuchi H; Fukushima S; Inoue K; Yoshikawa J
Lung Cancer; 2003 Aug; 41(2):123-30. PubMed ID: 12871775
[TBL] [Abstract][Full Text] [Related]
16. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
17. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS).
Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Marsland T; Patel T; Rubin M; White L; Yang JC; Klughammer B; Colburn D; Miller V; Johnson BE
J Thorac Oncol; 2014 Sep; 9(9):1411-7. PubMed ID: 25122437
[TBL] [Abstract][Full Text] [Related]
18. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of overexpressed matrix metalloproteinase-2, mouse-double minute: 2 homolog and epidermal growth factor receptor in non-small cell lung cancer.
Jiang LY; Bi R; Ding FB; Wang MS; Mei J; He Y
J BUON; 2016; 21(2):341-8. PubMed ID: 27273943
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor ligand/receptor loop and downstream signaling activation pattern in completely resected nonsmall cell lung cancer.
Volante M; Saviozzi S; Rapa I; Ceppi P; Cappia S; Calogero R; Novello S; Borasio P; Papotti M; Scagliotti GV
Cancer; 2007 Sep; 110(6):1321-8. PubMed ID: 17647268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
